Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design - PubMed (original) (raw)
Comparative Study
. 2010 Mar 15;427(1):19-28.
doi: 10.1042/BJ20091530.
Affiliations
- PMID: 20067443
- DOI: 10.1042/BJ20091530
Comparative Study
Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design
Charlotte A Dodson et al. Biochem J. 2010.
Erratum in
- Biochem J. 2010;427(3):551
Abstract
The production of selective protein kinase inhibitors is often frustrated by the similarity of the enzyme active sites. For this reason, it is challenging to design inhibitors that discriminate between the three Aurora kinases, which are important targets in cancer drug discovery. We have used a triple-point mutant of Aurora-A (AurAx3) which mimics the active site of Aurora-B to investigate the structural basis of MLN8054 selectivity. The bias toward Aurora-A inhibition by MLN8054 is fully recapitulated by AurAx3 in vitro. X-ray crystal structures of the complex suggest that the basis for the discrimination is electrostatic repulsion due to the T217E substitution, which we have confirmed using a single-point mutant. The activation loop of Aurora-A in the AurAx3-MLN8054 complex exhibits an unusual conformation in which Asp274 and Phe275 side chains point into the interior of the protein. There is to our knowledge no documented precedent for this conformation, which we have termed DFG-up. The sequence requirements of the DFG-up conformation suggest that it might be accessible to only a fraction of kinases. MLN8054 thus circumvents the problem of highly homologous active sites. Binding of MLN8054 to Aurora-A switches the character of a pocket within the active site from polar to a hydrophobic pocket, similar to what is observed in the structure of Aurora-A bound to a compound that induces DFG-out. We propose that targeting this pocket may be a productive route in the design of selective kinase inhibitors and describe the structural basis for the rational design of these compounds.
Similar articles
- Molecular dynamics and free energy studies on Aurora kinase A and its mutant bound with MLN8054: insight into molecular mechanism of subtype selectivity.
Yang Y, Shen Y, Li S, Jin N, Liu H, Yao X. Yang Y, et al. Mol Biosyst. 2012 Nov;8(11):3049-60. doi: 10.1039/c2mb25217a. Epub 2012 Sep 18. Mol Biosyst. 2012. PMID: 22990663 - A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
Aliagas-Martin I, Burdick D, Corson L, Dotson J, Drummond J, Fields C, Huang OW, Hunsaker T, Kleinheinz T, Krueger E, Liang J, Moffat J, Phillips G, Pulk R, Rawson TE, Ultsch M, Walker L, Wiesmann C, Zhang B, Zhu BY, Cochran AG. Aliagas-Martin I, et al. J Med Chem. 2009 May 28;52(10):3300-7. doi: 10.1021/jm9000314. J Med Chem. 2009. PMID: 19402633 - Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.
Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB, Claiborne CF. Manfredi MG, et al. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4106-11. doi: 10.1073/pnas.0608798104. Epub 2007 Feb 23. Proc Natl Acad Sci U S A. 2007. PMID: 17360485 Free PMC article. - Aurora A and B kinases as targets for cancer: will they be selective for tumors?
Matthews N, Visintin C, Hartzoulakis B, Jarvis A, Selwood DL. Matthews N, et al. Expert Rev Anticancer Ther. 2006 Jan;6(1):109-20. doi: 10.1586/14737140.6.1.109. Expert Rev Anticancer Ther. 2006. PMID: 16375648 Review. - Protein kinase inhibitors: insights into drug design from structure.
Noble ME, Endicott JA, Johnson LN. Noble ME, et al. Science. 2004 Mar 19;303(5665):1800-5. doi: 10.1126/science.1095920. Science. 2004. PMID: 15031492 Review.
Cited by
- Conformational heterogeneity of the BTK PHTH domain drives multiple regulatory states.
Lin DY, Kueffer LE, Juneja P, Wales TE, Engen JR, Andreotti AH. Lin DY, et al. Elife. 2024 Jan 8;12:RP89489. doi: 10.7554/eLife.89489. Elife. 2024. PMID: 38189455 Free PMC article. - Computational completion of the Aurora interaction region of N-Myc in the Aurora a kinase complex.
Altiner P, Çınaroğlu SS, Timucin AC, Timucin E. Altiner P, et al. Sci Rep. 2023 Oct 26;13(1):18399. doi: 10.1038/s41598-023-45272-3. Sci Rep. 2023. PMID: 37884585 Free PMC article. - Analysis of Predicted Amino Acid Sequences of Diatom Microtubule Center Components.
Petrova DP, Morozov AA, Potapova NA, Bedoshvili YD. Petrova DP, et al. Int J Mol Sci. 2023 Aug 14;24(16):12781. doi: 10.3390/ijms241612781. Int J Mol Sci. 2023. PMID: 37628962 Free PMC article. - A biophysical framework for double-drugging kinases.
Kim C, Ludewig H, Hadzipasic A, Kutter S, Nguyen V, Kern D. Kim C, et al. Proc Natl Acad Sci U S A. 2023 Aug 22;120(34):e2304611120. doi: 10.1073/pnas.2304611120. Epub 2023 Aug 17. Proc Natl Acad Sci U S A. 2023. PMID: 37590418 Free PMC article. - The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies.
Nitulescu GM, Stancov G, Seremet OC, Nitulescu G, Mihai DP, Duta-Bratu CG, Barbuceanu SF, Olaru OT. Nitulescu GM, et al. Molecules. 2023 Jul 12;28(14):5359. doi: 10.3390/molecules28145359. Molecules. 2023. PMID: 37513232 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous